Year |
Citation |
Score |
2020 |
Godsey JH, Silvestro A, Barrett JC, Bramlett K, Chudova D, Deras I, Dickey J, Hicks J, Johann DJ, Leary R, Lee JSH, McMullen J, McShane L, Nakamura K, Richardson AO, et al. Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC's Analytical Variables Working Group. Clinical Chemistry. 66: 1156-1166. PMID 32870995 DOI: 10.1093/Clinchem/Hvaa164 |
0.331 |
|
2020 |
Artieri C, Axelrod H, Baca A, Burke J, Chudova D, Dahdouli M, Ghadiri F, Hartwig A, He Y, Hite D, Jaimovich A, Juntilla M, Kurata J, Kong Y, Nance T, et al. Analytical validation of a tissue agnostic ctDNA MRD assay using tumor specific methylation and somatic variant profiles in early-stage CRC. Journal of Clinical Oncology. 38: e15549-e15549. DOI: 10.1200/Jco.2020.38.15_Suppl.E15549 |
0.482 |
|
2020 |
Yablonovitch A, Gnerre S, Kiedrowski LA, Yen J, Liu L, Helman E, Fairclough SR, Nagy R, Chudova D, Talasaz A. Identification of FGFR2/3 fusions from clinical cfDNA NGS using a de novo fusion caller. Journal of Clinical Oncology. 38: 3545-3545. DOI: 10.1200/Jco.2020.38.15_Suppl.3545 |
0.331 |
|
2020 |
Yen J, Gnerre S, Barbacioru C, Helman E, Manor O, Yablonovitch A, Satya RV, Liu L, Saam J, Fairclough S, Nagy B, Lanman R, Chudova D, Talasaz A. Abstract 729: Landscape of homologous recombination repair (HRR) mutations in prostate cancer profiled by ctDNA next-generation sequencing Clinical Trials. 80: 729-729. DOI: 10.1158/1538-7445.Am2020-729 |
0.438 |
|
2020 |
Westesson O, Axelrod H, Dean J, He Y, Sample P, Zotenko E, McCole R, Goel M, Eid C, Kurata J, Kong Y, Hartwig A, Snyder M, Greenleaf W, Raymond VM, ... Chudova D, et al. Abstract 2316: Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer Cancer Research. 80: 2316-2316. DOI: 10.1158/1538-7445.Am2020-2316 |
0.381 |
|
2019 |
Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, ... ... Chudova DI, et al. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31383735 DOI: 10.1158/1078-0432.Ccr-19-1324 |
0.377 |
|
2019 |
Zhao J, Fairclough SR, Chudova D, Lanman R, Talasaz A, Hardin A. Abstract 3769: Detection of allele specific loss of heterozygosity in 70,000 patients with ctDNA Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3769 |
0.308 |
|
2019 |
Yen J, Quinn K, Helman E, Chursov A, Nance T, Jaimovich A, Banks K, Franovic A, Gleitsman K, Latham J, Yablonovitch A, Sikora M, Fairclough S, Chudova D, Lanman RB, et al. Abstract 2509: Analysis of clonal hematopoiesis-associated mutations in the cell-free DNA of advanced cancer patients Cancer Research. 79: 2509-2509. DOI: 10.1158/1538-7445.Sabcs18-2509 |
0.448 |
|
2019 |
Barbacioru C, Raymond VM, Sikora M, Helman E, Gnerre S, Fairclough S, Chudova D, Lanman RB, Talasaz A. Abstract 435: Cell-free circulating tumor DNA (ctDNA) detects somatic copy number loss in homologous recombination repair genes Cancer Research. 79: 435-435. DOI: 10.1158/1538-7445.Am2019-435 |
0.504 |
|
2019 |
Quinn K, Helman E, Nance T, Yen J, Latham J, Gleitsman K, Vijaya-Satya R, Artieri C, Artyomenko A, Sikora M, Chudova D, Lanman RB, Talasaz A. Abstract 3404: Landscape and genomic correlates of ctDNA-based tumor mutational burden across six solid tumor types Cancer Research. 79: 3404-3404. DOI: 10.1158/1538-7445.Am2019-3404 |
0.471 |
|
2019 |
Zhao J, Artyomenko A, Artieri C, Latham J, Fairclough SR, Barbacioru C, Helman E, Strickler J, Chudova D, Lanman R, Talasaz A. Abstract 1675: Analytical validation of MSI High detection with GuardantOMNI Cancer Research. 79: 1675-1675. DOI: 10.1158/1538-7445.Am2019-1675 |
0.488 |
|
2018 |
Quinn K, Helman E, Nance T, Artieri C, Yen J, Zhao J, Fairclough S, Sikora M, Chudova D, Lanman RB, Talasaz A. Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii41. PMID 32137025 DOI: 10.1093/Annonc/Mdy269.129 |
0.393 |
|
2018 |
Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, et al. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800328. PMID 30339520 DOI: 10.1200/Jco.18.00328 |
0.481 |
|
2018 |
Zill OA, Banks KC, Fairclough SR, Mortimer S, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, Talasaz A. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29776953 DOI: 10.1158/1078-0432.Ccr-17-3837 |
0.414 |
|
2018 |
Overman MJ, Jaimovich A, Kennedy D, Tan M, Gavino D, Mortimer S, Chudova D, Talasaz A, Odegaard J, Kopetz S. A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype. Journal of Clinical Oncology. 36: 12044-12044. DOI: 10.1200/Jco.2018.36.15_Suppl.12044 |
0.368 |
|
2018 |
Artieri CG, Sikora M, Artyomenko A, Helman E, Chudova D, Lanman R, Talasaz A. Abstract 636: Accounting for processed pseudogene-related artifacts improves specificity of clinical cancer diagnostic sequencing Cancer Research. 78: 636-636. DOI: 10.1158/1538-7445.Am2018-636 |
0.452 |
|
2018 |
Helman E, Artieri C, Vowles JV, Yen J, Nance T, Sikora M, Gourneau J, Goel M, Mortimer S, Chudova D, Odegaard J, Lanman RB, Talasaz A. Abstract 5603: Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research Cancer Research. 78: 5603-5603. DOI: 10.1158/1538-7445.Am2018-5603 |
0.489 |
|
2018 |
Nance T, Helman E, Artieri C, Yen J, Slavin TP, Chudova D, Lanman RB, Talasaz A. Abstract 4272: A novel approach to differentiation of somatic vs. germline variants in liquid biopsies using a betabinomial model Cancer Research. 78: 4272-4272. DOI: 10.1158/1538-7445.Am2018-4272 |
0.442 |
|
2018 |
Fairclough S, Zill O, Barbacioru C, Odegaard J, Lanman RB, Talasaz A, Chudova D. Abstract 2190: A method for differentiating clonal driver mutations from subclonal emerging resistance mutations in circulating cell-free DNA Tumor Biology. DOI: 10.1158/1538-7445.Am2018-2190 |
0.363 |
|
2018 |
Barbacioru C, Collisson E, Chudova D, Odegaard J, Lanman R, Talasaz A. Abstract 1183: Targeted sequencing of cell-free DNA data enables comprehensive profiling of tumor copy number landscape from blood Cancer Research. 78: 1183-1183. DOI: 10.1158/1538-7445.Am2018-1183 |
0.507 |
|
2018 |
Artyomenko A, Sikora M, Lefterova M, Raymond V, Gavino D, Barbacioru C, Artieri C, Helman E, Chudova D, Lanman R, Odegaard J, Willis J, Fakih M, Kopetz S, Talasaz A. Microsatellite instability detection by targeted sequencing of cell-free DNA Annals of Oncology. 29: viii424. DOI: 10.1093/Annonc/Mdy288.063 |
0.398 |
|
2017 |
Maslan A, Jaimovich A, Rajagopalan N, Tan M, Mortimer S, Chudova D, Kennedy D, Kim HC, Kim ST, Lee S, Lee J, Eltoukhy H, Kim J, Talasaz A. Post resection circulating residual disease monitoring in early stage lung and colorectal cancer patients using a circulating cell-free DNA assay with ultra-high accuracy and specificity. Journal of Clinical Oncology. 35: e23068-e23068. DOI: 10.1200/Jco.2017.35.15_Suppl.E23068 |
0.478 |
|
2017 |
Slavin TP, Banks K, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek M, Lilly MB, Sonpavde G, et al. Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. Journal of Clinical Oncology. 35: 1514-1514. DOI: 10.1200/Jco.2017.35.15_Suppl.1514 |
0.511 |
|
2017 |
Abdueva D, Eltoukhy H, Chudova D, Talasaz A. Abstract 3350: Cell-free DNA fragmentation patterns analyzed in over 15000 cancer patients reveal changes associated with tumor somatic mutations and result in improved sensitivity and specificity of somatic variant detection Cancer Research. 77: 3350-3350. DOI: 10.1158/1538-7445.Am2017-3350 |
0.535 |
|
2017 |
Pal S, Brooks C, Chudova D, Odegaard J, Gandara D, Mack P, Mortimer S, Banks K, Nagy R, Baca A, Lanman R, Eltoukhy H, Talasaz A. Clinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNA Annals of Oncology. 28: v596. DOI: 10.1093/Annonc/Mdx391.002 |
0.467 |
|
2017 |
Mack P, Banks K, Riess J, Zill O, Mortimer S, Chudova D, Odegaard J, Lee C, Nagy R, Eltoukhy H, Talasaz A, Lanman R, Gandara DR. OA06.01 Clinical Utility of Circulating Tumor DNA (ctDNA) Analysis by Digital next Generation Sequencing of over 5,000 Advanced NSCLC Patients Journal of Thoracic Oncology. 12: S263-S264. DOI: 10.1016/J.Jtho.2016.11.256 |
0.432 |
|
2016 |
Zill OA, Mortimer S, Banks KC, Nagy RJ, Chudova D, Jackson C, Baca A, Ye JZ, Lanman RB, Talasaz A, Eltoukhy H, Kurzrock R. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. Journal of Clinical Oncology. 34: LBA11501-LBA11501. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba11501 |
0.515 |
|
2016 |
Lee CE, Lanman RB, Banks KC, Nagy RJ, Mortimer S, Simon DA, Chudova D, Eltoukhy H, Talasaz A, Lastra E, Kopetz S, Strickler JH. Identification of novel EGFR ectodomain mutations based on a large database of clinical circulating cell-free DNA sequencing tests. Journal of Clinical Oncology. 34: e23167-e23167. DOI: 10.1200/Jco.2016.34.15_Suppl.E23167 |
0.469 |
|
2016 |
Fairclough SR, Zill OA, Chudova D, Lee CE, Lanman RB, Banks KC, Nagy RJ, Mortimer S, Eltoukhy H, Talasaz A, Ramalingam SS. Case series of EGFR C797S mutations in non-small cell lung cancer identified with cell-free circulating tumor DNA next generation sequencing. Journal of Clinical Oncology. 34: e23021-e23021. DOI: 10.1200/Jco.2016.34.15_Suppl.E23021 |
0.429 |
|
2016 |
Ihuegbu N, Banks KC, Fairclough SR, Zill OA, Chudova D, Lanman RB, Blakely CM. Non-invasive detection of crizotinib resistance in ALK-rearranged lung adenocarcinoma directs treatment with next-generation ALK inhibitors. Journal of Clinical Oncology. 34: e20643-e20643. DOI: 10.1200/Jco.2016.34.15_Suppl.E20643 |
0.321 |
|
2016 |
Abdueva D, Chudova D, Lanman RB, Banks KC, Nagy RJ, Mortimer S, Talasaz A, Eltoukhy H, Kurzrock R. Detection, frequency and actionability of recurrent copy number gains detected by non-invasive liquid biopsy of 3,942 lung and breast cancer samples. Journal of Clinical Oncology. 34: 11541-11541. DOI: 10.1200/Jco.2016.34.15_Suppl.11541 |
0.445 |
|
2016 |
Mortimer S, Dilger K, Abdueva D, Chudova D, Sarin A, Atreya CE, Leng J, Lee J, Eltoukhy H, Munster PN, Talasaz A. Early, molecular detection of cancer utilizing circulating cell-free DNA assay with ultra high accuracy and sensitivity. Journal of Clinical Oncology. 34: 11540-11540. DOI: 10.1200/Jco.2016.34.15_Suppl.11540 |
0.479 |
|
2016 |
Mortimer SA, Dilger K, Fairclough S, Abdueva D, Chudova D, Sarin A, Leng J, Lee J, Eltoukhy H, Talasaz A. Abstract 506: Post-surgical resection monitoring in early stage colorectal carcinoma patients using a circulating cell-free DNA assay with ultra-high accuracy and specificity Cancer Research. 76: 506-506. DOI: 10.1158/1538-7445.Am2016-506 |
0.489 |
|
2014 |
Chitty L, Sehnert A, Jones K, Hill M, Abdueva D, Chudova D, Rava R. 201: Detection of DiGeorge and Cri du Chat syndrome deletions from maternal plasma by deep sequencing cell free DNA (cfDNA) American Journal of Obstetrics and Gynecology. 210. DOI: 10.1016/J.Ajog.2013.10.234 |
0.375 |
|
Show low-probability matches. |